Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 9:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Treatment Arm Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

Analysis of the Effect of Antimicrobial Soap on Bacterial Survival

NCT02012348
View directory record Official record
Conditions
Survival of Bacteria on Skin After Using Different Soaps
Interventions
Antibacterial soap with triclocarban, Antibacterial soap + benzalkonium chloride, Control soap
Other
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 2, 2019 · Synced Sep 25, 2026, 9:57 AM EDT
Completed Not applicable Interventional

Online Imaginal Exposure

NCT03712748
View directory record Official record
Conditions
Eating Disorder, Exposure, Anorexia Nervosa, Bulimia Nervosa, Binge-Eating Disorder, Therapy
Interventions
Imaginal Exposure therapy
Behavioral
Lead sponsor
University of Louisville
Other
Eligibility
14 Years and older
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 24, 2021 · Synced Sep 25, 2026, 9:57 AM EDT
Completed Not applicable Interventional

Offering Support and Electronic Resources for Care Partners of Those With Multiple Sclerosis

NCT04662008
View directory record Official record
Conditions
Multiple Sclerosis, Caregivers
Interventions
Tele-coaching, Website
Behavioral
Lead sponsor
Case Western Reserve University
Other
Eligibility
18 Years and older
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 30, 2022 · Synced Sep 25, 2026, 9:57 AM EDT
Completed Early Phase 1 Interventional

Immunotherapy + Radiation in Resectable Soft Tissue Sarcoma

NCT03463408
View directory record Official record
Conditions
Sarcoma
Interventions
nivolumab, ipilimumab
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 25, 2026, 9:57 AM EDT
Completed Phase 1 Interventional

FdCyd and THU for Advanced Solid Tumors

NCT01534598
View directory record Official record
Conditions
Neoplasms
Interventions
FdCyd + THU
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2025
U.S. locations
6
States / cities
Duarte, California • Los Angeles, California • Sacramento, California + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Sep 25, 2026, 9:57 AM EDT
Completed Not applicable Interventional

Delivery of Anxiety Disorder Treatment in Addictions Centers

NCT01764698
View directory record Official record
Conditions
Anxiety Disorders, Substance Use Disorders
Interventions
CALM-SUD, Treatment as usual
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 60 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 25, 2017 · Synced Sep 25, 2026, 9:57 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Mobile App Logging for Diabetes in Pregnancy

NCT06005987
View directory record Official record
Conditions
Gestational Diabetes Mellitus in Pregnancy, Type 2 Diabetes
Interventions
OneTouch Reveal application
Behavioral
Lead sponsor
Carolyn Zahler-Miller
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 30, 2025 · Synced Sep 25, 2026, 9:57 AM EDT
Completed Not applicable Interventional Results available

Chest Pain Perception and Capsaicin Sensitivity in Patients With Acute Cardiac Ischemia

NCT02346916
View directory record Official record
Conditions
Chest Pain
Interventions
Capsaicin
Drug
Lead sponsor
Bassett Healthcare
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Cooperstown, New York
Source: ClinicalTrials.gov public record
Updated Mar 3, 2021 · Synced Sep 25, 2026, 9:57 AM EDT
Terminated Not applicable Interventional

Connected Pens for Diabetes Study

NCT03830216
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Connected insulin pen and smartphone app, Inactive connected insulin pen without smartphone app
Device
Lead sponsor
Companion Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Jan 26, 2021 · Synced Sep 25, 2026, 9:57 AM EDT
Enrolling by invitation Not applicable Interventional

Virtual Nurse and Social Worker Palliative Care Team to Improve Quality of Life in Veterans With Heart Failure or COPD

NCT07714252
View directory record Official record
Conditions
Heart Failure, Pulmonary Disease, Chronic Obstructive, Interstitial Lung Disease
Interventions
Virtual Nurse and Social Worker Palliative Care Team, Enhanced Implementation Support, Standard Implementation Support
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
7
States / cities
Phoenix, Arizona • Long Beach, California • Aurora, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 25, 2026, 9:57 AM EDT
Active, not recruiting Phase 3 Interventional

Dry Mouth Toothpaste Study - Comparing Two Toothpastes With Arginine

NCT06365047
View directory record Official record
Conditions
Xerostomia
Interventions
8% Arginine toothpaste, 1000 ppm F toothpaste
Device · Drug
Lead sponsor
Tufts University
Other
Eligibility
18 Years to 80 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Sep 25, 2026, 9:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to a Malaria Vaccine (MSP1 42-C1) With or Without CPG 7909 Adjuvant

NCT00320658
View directory record Official record
Conditions
Malaria
Interventions
MSP1 42-C1/Alhydrogel, CPG 7909
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 20, 2008 · Synced Sep 25, 2026, 9:57 AM EDT
Completed Phase 1 Interventional

Safety Study of IL-21/Anti-PD-1 Combination in the Treatment of Solid Tumors

NCT01629758
View directory record Official record
Conditions
Neoplasms by Site
Interventions
Denenicokin, Nivolumab
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
5
States / cities
Scottsdale, Arizona • New Haven, Connecticut • Tampa, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2015 · Synced Sep 25, 2026, 9:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study in Normal Healthy People, Testing Different Versions of a Pill That Will be Used to Treat Rheumatoid Arthritis.

NCT00838058
View directory record Official record
Conditions
Rheumatoid Arthritis, Healthy Volunteers
Interventions
CE 224,535
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 13, 2009 · Synced Sep 25, 2026, 9:57 AM EDT
Recruiting Phase 4 Interventional

Novel Extended-Release Bupivacaine Polymer for Sustained Pain Relief Following Total Knee Arthroplasty

NCT07775248
View directory record Official record
Conditions
Osteoarthritis (OA) of the Knee
Interventions
Periarticular Injection, Adductor Canal Block, Bupivacaine-Meloxicam
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Grosse Pointe Farms, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 25, 2026, 9:57 AM EDT
Completed Not applicable Interventional

Healing Touch or Guided Imagery In Treating Pain, Fatigue, Nausea, and Anxiety in Patients Undergoing Chemotherapy

NCT01553578
View directory record Official record
Conditions
Anxiety Disorder, Fatigue, Malignant Neoplasm, Nausea and Vomiting, Pain
Interventions
questionnaire administration, therapeutic touch, management of therapy complications, standard follow-up care
Other · Procedure · Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 4, 2018 · Synced Sep 25, 2026, 9:57 AM EDT
Completed Phase 2 Interventional Results available

Topical Dexamethasone and Tacrolimus for the Treatment of Oral Chronic Graft-Versus-Host Disease

NCT00686855
View directory record Official record
Conditions
Oral Chronic Graft-versus-host Disease
Interventions
Tacrolimus, Dexamethasone
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
4 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
5
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 19, 2014 · Synced Sep 25, 2026, 9:57 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Rituximab and Liposomal Doxorubicin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

NCT00244985
View directory record Official record
Conditions
Lymphoma
Interventions
rituximab, pegylated liposomal doxorubicin hydrochloride
Biological · Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 16, 2017 · Synced Sep 25, 2026, 9:57 AM EDT
Completed Phase 2 Interventional

Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma

NCT00026143
View directory record Official record
Conditions
Recurrent Melanoma, Stage IV Melanoma
Interventions
recombinant interleukin-12, recombinant interferon alfa, laboratory biomarker analysis
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 4, 2013 · Synced Sep 25, 2026, 9:57 AM EDT
Completed Phase 2Phase 3 Interventional Results available

A Trial Investigating Safety and Efficacy of Treatment With BAY94-9027 in Severe Hemophilia A

NCT01580293
View directory record Official record
Conditions
Hemophilia A
Interventions
BAY94-9027
Biological
Lead sponsor
Bayer
Industry
Eligibility
12 Years to 65 Years · Male only
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
14
States / cities
Tucson, Arizona • Sacramento, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2023 · Synced Sep 25, 2026, 9:57 AM EDT
Completed Phase 2 Interventional Results available

Tivantinib in Treating Patients With Metastatic Prostate Cancer

NCT01519414
View directory record Official record
Conditions
Hormone-Resistant Prostate Cancer, Prostate Adenocarcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
Interventions
Laboratory Biomarker Analysis, Placebo, Tivantinib
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
20
States / cities
Washington D.C., District of Columbia • Tampa, Florida • Chicago, Illinois + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2018 · Synced Sep 25, 2026, 9:57 AM EDT
Recruiting Phase 1Phase 2 Interventional

Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma

NCT03011814
View directory record Official record
Conditions
Folliculotropic Mycosis Fungoides, Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent Mycosis Fungoides, Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Mycosis Fungoides, Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified, Sezary Syndrome, Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma
Interventions
Durvalumab, Laboratory Biomarker Analysis, Lenalidomide
Biological · Other · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2030
U.S. locations
4
States / cities
Duarte, California • New York, New York • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 25, 2026, 9:57 AM EDT
Terminated Not applicable Interventional

A Sham-Controlled Study to Evaluate the Safety and Efficacy of a Smart, Self-Adjusting, Surgery-Free, Wearable Bladder Neuromodulation System for Overactive Bladder

NCT05381116
View directory record Official record
Conditions
Overactive Bladder, Urinary Urge Incontinence, Urge Incontinence
Interventions
Avation System, Sham Avation System
Device
Lead sponsor
Avation Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
6
States / cities
Tucson, Arizona • Oak Lawn, Illinois • New Orleans, Louisiana + 3 more
Source: ClinicalTrials.gov public record
Updated May 28, 2024 · Synced Sep 25, 2026, 9:57 AM EDT
Active, not recruiting Phase 3 Interventional

BCG in Combination With Durvalumab in Adult BCG-naïve, High-risk NMIBC Participants

NCT05943106
View directory record Official record
Conditions
Non-Muscle- Invasive Bladder Cancer
Interventions
Durvalumab, BCG
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
19
States / cities
Phoenix, Arizona • Little Rock, Arkansas • San Diego, California + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 25, 2026, 9:57 AM EDT